CD20
Assets acting on this target.
- Class
- Anti-CD20 monoclonal antibody
- Pathway
- B-cell depletion
CD20 is a cell-surface protein expressed on B lymphocytes, a class of white blood cells responsible for producing antibodies and, in some diseases, for driving damaging immune activity. CD20 appears at a defined stage of B-cell development and is retained on most mature B cells, but it is absent from the earliest precursor cells and from the plasma cells that ultimately secrete antibodies. This expression pattern makes it an attractive target: antibodies directed against CD20 can eliminate the pool of circulating and tissue-resident B cells implicated in disease while sparing the stem-cell compartment needed to regenerate the immune system and largely sparing long-lived plasma cells. Depleting B cells interrupts several disease-relevant processes, including production of harmful autoantibodies, presentation of antigens to other immune cells, and secretion of inflammatory signaling molecules. This rationale underlies the use of anti-CD20 antibodies across B-cell malignancies, where the target cells are themselves the tumor population, and across autoimmune conditions such as those affecting the nervous system or joints, where B cells contribute to disease even though they are not cancerous. Because CD20 does not shed from the cell surface or circulate freely in blood, it remains a stable, accessible target for antibody binding throughout treatment.
By indication
Related mechanisms
CD20 drugs compared
16 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Obinutuzumab | Roche | monoclonal antibody | Approved | Approved in Chronic Lymphocytic Leukemia; Approved in Follicular Lymphoma; Approved in Lupus Nephritis; Approved in Primary Membranous Nephropathy; Phase 3 in Non-Hodgkin Lymphoma |
| Ocrelizumab | Roche | monoclonal antibody | Approved | Approved in Multiple Sclerosis |
| Ocrevus Zunovo | Roche | monoclonal antibody + enzyme | Approved | Approved in Multiple Sclerosis |
| Ofatumumab | Novartis | monoclonal antibody | Approved | Approved in Multiple Sclerosis |
| PF-05280586 | Pfizer | biologic (registry-typed, subtype undisclosed) | Approved | Approved in B-Cell Non-Hodgkin Lymphoma; Approved in Chronic Lymphocytic Leukemia; Approved in Diffuse Large B-Cell Lymphoma; Approved in Follicular Lymphoma; Approved in Large B-Cell Lymphoma; Approved in Non-Hodgkin Lymphoma; Approved in Relapsed/Refractory Non-Hodgkin Lymphoma; Approved in Rheumatoid Arthritis |
| RituximabRituxan | Biogen, Chugai Pharma, Roche, Zenyaku Kogyo | monoclonal antibody | Approved | Approved in Chronic Lymphocytic Leukemia; Approved in Diffuse Large B-Cell Lymphoma; Approved in Follicular Lymphoma; Approved in Rheumatoid Arthritis |
| Rituximab-abbs (Truxima)Truxima | Celltrion, Teva Pharmaceutical Industries | monoclonal antibody | Approved | Approved in Chronic Lymphocytic Leukemia; Approved in Non-Hodgkin Lymphoma; Approved in Rheumatoid Arthritis |
| UblituximabBriumvi | Neuraxpharm, TG THERAPEUTICS, INC. | monoclonal antibody | Approved | Approved in Multiple Sclerosis; Phase 2 in Myasthenia Gravis; Phase 2 in Schizophrenia |
| ABP 692 | Amgen | monoclonal antibody | Phase 3 | Phase 3 in Multiple Sclerosis |
| Acellbia | Biocad | monoclonal antibody | Phase 3 | Phase 3 in Rheumatoid Arthritis |
| BCD-281 | Biocad | monoclonal antibody | Phase 3 | Phase 3 in Multiple Sclerosis |
| CT-P53 | Celltrion | monoclonal antibody | Phase 3 | Phase 3 in Multiple Sclerosis |
| DivozilimabIvlizi | Biocad | monoclonal antibody | Phase 3 | Phase 3 in Multiple Sclerosis; Phase 3 in Systemic Sclerosis; Phase 1 in Systemic Lupus Erythematosus |
| HLX01Hanlikang | Shanghai Henlius Biotech | monoclonal antibody | Phase 3 | Phase 3 in Rheumatoid Arthritis |
| Obinutuzumab beta (Bejescin)Bejescin | Beijing Mabworks Biotech Co., Ltd., Everest Medicines (Beijing) Co., Ltd. | monoclonal antibody | Phase 3 | Phase 3 in Follicular Lymphoma; Phase 3 in Primary Membranous Nephropathy; Phase 3 in Systemic Lupus Erythematosus |
| SAR448501 | Sanofi | bispecific antibody | Phase 1 | Phase 1 in Rheumatoid Arthritis; Phase 1 in Systemic Lupus Erythematosus |